Trial Profile
A Multicenter, Single-Arm, Open-Label Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients From Birth to < 1 Year With Influenza-Like Symptoms
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational
- Acronyms MINISTONE-1
- Sponsors Roche
- 09 Aug 2023 Status changed from recruiting to completed.
- 19 Aug 2022 Planned End Date changed from 2 Aug 2022 to 1 Aug 2023.
- 19 Aug 2022 Planned primary completion date changed from 2 Aug 2022 to 1 Aug 2023.